To access this material please log in or register

Register Authorize

Value of HLA antigen system in development of DCMP in Byelorussian population group

Zhuyko E. N., Semenov G. V., Kardash O. F., Bulgak A. G.

Keywords: genetic markers, DCMP, HLA system

DOI: 10.18087/rhfj.2012.3.1619

Relevance. Studies in the Western Europe, Northern America and Japan evaluated predisposition to DCMP development in presence of specific antigens of the main histoincompatibility complex (HCM) responsible for development of an inflammatory response. Objective. To evaluate the frequency of HLA antigens prevalance in patients with DCMP in Byelorussian population group with the help of DNA-genotyping. Materials and methods. The study included 71 men with the established diagnosis of DCMP with clinical signs of CHF of Stage IIА – IIБ (NYHA, class II–III), residing in the territory of Republic Byelorus. HLA-typing was conducted by serological method and with use of PCR-SSP technology. Data of typing of randomly chosen donors without autoimmune diseases and family record by them were used as control. Results. The average age of patients made 42 (24;61) years. Due to the clinically confirmed DCMP the patients were observed at the average for 5 (1;18) years. The ejection fraction of LV was reduced to 21.04±0,78 %. Among patients with DCMP and healthy donors (n=200) differences were destroketed by haplotype А2В44 of class I of the main complex. In patients with DCMP (19.7 %) this halotype occurred reliably more frequently (χ2=5.45, ОР=2.32, р=0.02;) than among donors (8.5 %). When comparing DR of II class angigens МНС patients with DCMP with a genotype of donors a reliable difference by the frequency of antigen DRВ1*04 prevalence is observed (32.3 and 17% respectively in patients with DCMP and donors, χ2=4.84 ОР=1.91, р=0.028). The prevalence of the most prognosticaly unfavourable allele HLA-DRВ1*04 in the Byelorussian population is lower than in the selection of patients as well as in healthy persons in populations of the Caucasian race of the Northern America and Western Europe (54 and 32 % respectively in patients and healthy persons), but comparable to the prevalence of this allele among healthy persons of Caucasian race in the Russian Federation (14 %), which signifies ethnic differences in the genotype of the considered populations. When analyzing the relation of clinical and demographic data and genotype of HLA-system it was established that the age of patients with a combination А2В44 and DRВ1*04 was reliably much higher than the age of patients having only halotype А2В44 or allele DRВ1*04, as well as other genotypes. Conclusion. The obtained results confirm the associative connection of DCMP with antigens of HLA – complex in the Byelorussian population. The detected associations might be used for forecasting of DCMP development and individualization of a complex of therapy and preventive measures.
  1. Elliott P, Andersson B, Arbustini E et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29 (2):270–276.
  2. Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113 (14):1807–1816.
  3. Yoshikawa T. Contribution of acquired factors to the pathogenesis of dilated cardiomyopathy. -The cause of dilated cardiomyopathy: genetic or acquired? (Acquired-Side). Circ J. 2011;75 (7):1766–1773; discussion 1773.
  4. Anderson JL, Carlquist JF, Hammond EH. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy. Lancet. 1982;2 (8308):1124–1127.
  5. Herskowitz A, Ahmed-Ansari A, Neumann DA et al. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol. 1990;15 (3):624–632.
  6. Caforio AL, Keeling PJ, Zachara E et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet. 1994;344 (8925):773–777.
  7. Caforio AL, Bonifacio E, Stewart JT et al. Novel organ-specific circula­ting cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol. 1990;15 (7):1527–1534.
  8. Kimura A. Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: the cause of dilated cardiomyopathy: genetic or acquired? (genetic-side). Circ J. 2011;75 (7):1756–1765; discussion 1765.
  9. Амосова Е. Н. Кардиомиопатии. – Киев: «Книга Плюс», 1999. – 421 с.
  10. Krzanowski JJ. Human major histocompatibility complex. Genes and diseases. J Fla Med Assoc. 1992;79 (2):97–99.
  11. Chang CH, Flavell RA. Class II transactivator regulates the expression of multiple genes involved in antigen presentation. J Exp Med. 1995;181 (2):765–767.
  12. Anderson JL, Carlquist JF, Lutz JR et al. HLA A, B and DR typing in idiopathic dilated cardiomyopathy: a search for immune response factors. Am J Cardiol. 1984;53 (9):1326–1330.
  13. Limas CJ, Limas C. HLA antigens in idiopathic dilated cardiomyopathy. Br Heart J. 1989;62 (5):379–383.
  14. Limas C, Limas CJ, Boudoulas H et al. Anti-beta-receptor antibodies in familial cardiomyopathy: correlation with HLA-DR and HLA-DQ gene polymorphisms. Am Heart J. 1994;127 (2):382–386.
  15. Smith JD, Rose ML, Pomerance A et al. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet. 1995;346 (8986):1318–1322.
  16. Limas CJ, Limas C. Beta-adrenoceptor antibodies and genetics in dilated cardiomyopathy--an overview and review. Eur Heart J. 1991;12 (Suppl D): 175–177.
  17. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31 (6):355–360.
  18. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4 (4):411–417.
  19. Jin B, Luo XP, Ni HC et al. A meta-analysis of HLA-DR polymorphism and genetic susceptibility to idiopathic dilated cardiomyopathy. Mol Biol Rep. 2012;39 (1):221–226.
  20. Хромова Н. А. Полиморфизм системы HLA у представителей разных славянских этнических групп (русской, белорусской и украинской) (рус.). Автореферат дис…. к. м. н. – М.: 2005. – 29 с.
  21. Nishi H, Koga Y, Koyanagi T et al. DNA typing of HLA class II genes in Japanese patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1995;27 (10):2385–2392.
Zhuyko E. N., Semenov G. V., Kardash O. F. et al. Value of HLA antigen system in development of DCMP in Byelorussian population group. Russian Heart Failure Journal. 2012;13(3):172-175

To access this material please log in or register

Register Authorize
Ru En